← Leaderboards
Kristy Perez
Civatech Oncology, Inc.
$9,817,743
Attributed
$9,817,743
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,817,743 · 3
By mechanism
R44$8,818,779 · 2
N44$998,964 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Source”
- Richard A Gibbs · Baylor College Of Medicine$285,393,445
- David Heimbrook · Leidos Biomedical Research, Inc.$233,184,481
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- Jeffrey P Krischer · University Of South Florida$224,745,020
- Albert Lazzarini · California Institute Of Technology$202,317,285
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$155,571,437
Research focus
SourceRadiation TherapyBrachytherapyTissuesRadiationStructurePalladium 103DoseDevicesOverdoseOncologyEncapsulatedOperative Surgical ProceduresImplantRecurrenceMinimally InvasiveSideExcisionMembraneLocalized Malignant NeoplasmMalignant NeoplasmsClinical TrialsMissionPolymers
Grant awards (12)
Commercializing CivaSheet for Pancreatic Cancer Patients$1,017,318
R44 · FY2025 · CA · contact PI
Commercializing CivaSheet for Pancreatic Cancer Patients$1,117,042
R44 · FY2024 · CA · contact PI
Commercializing CivaSheet for Pancreatic Cancer Patients$1,864,846
R44 · FY2023 · CA · contact PI
Administrative Supplement for the Evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer$220,413
R44 · FY2021 · CA · contact PI
Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer$595
R44 · FY2020 · CA · contact PI
Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer$801,730
R44 · FY2019 · CA · contact PI
Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer$1,165,750
R44 · FY2018 · CA · contact PI
Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers$570,035
R44 · FY2018 · CA · contact PI
Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers$1,464,585
R44 · FY2017 · CA · contact PI
Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer$296,866
R44 · FY2017 · CA · contact PI
Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers$299,599
R44 · FY2016 · CA · contact PI
OTHER FUNCTIONS "DEVELOPMENT OF A UNI-DIRECTIONAL BRACHYTHERAPY DEVICE FOR THE T$998,964
N44 · FY2012 · CA · contact PI